Ocuphire Pharma Gross Profit 2010-2024 | IRD

Ocuphire Pharma gross profit from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Ocuphire Pharma Annual Gross Profit
(Millions of US $)
2023 $19
2022 $40
2021 $1
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Ocuphire Pharma Quarterly Gross Profit
(Millions of US $)
2024-06-30 $1
2024-03-31 $2
2023-12-31 $2
2023-09-30 $12
2023-06-30 $4
2023-03-31 $2
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30 $0
2010-03-31 $0
2009-12-31
2009-09-30 $0
2009-06-30 $0
2009-03-31 $0
Sector Industry Market Cap Revenue
$0.000B $0.000B
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
Stock Name Country Market Cap PE Ratio
Fanhua (AIFU) China $0.086B 2.07
Top KingWin (WAI) China $0.008B 0.00
S&W Seed (SANW) United States $0.006B 0.00
Invo BioScience (NAYA) United States $0.004B 0.00